MARKET

DVAX

DVAX

Dynavax Technolo
NASDAQ
11.80
+0.34
+2.92%
Opening 13:45 05/22 EDT
OPEN
11.43
PREV CLOSE
11.46
HIGH
11.96
LOW
11.40
VOLUME
694.83K
TURNOVER
0
52 WEEK HIGH
15.15
52 WEEK LOW
10.48
MARKET CAP
1.54B
P/E (TTM)
235.90
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DVAX last week (0513-0517)?
Weekly Report · 2d ago
Analysts Forecast 11% Gains Ahead For The Holdings of SPSM
NASDAQ · 6d ago
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
TipRanks · 05/14 17:30
Dynavax Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones · 05/14 15:30
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target
Benzinga · 05/14 15:19
Hold Rating on Dynavax Amidst FDA Setback and Long-term Profitability Focus
TipRanks · 05/14 14:25
Dynavax Receives FDA's CRL Regarding Four-Dose Heplisav-B Vaccine For Hemodialysis Patients
NASDAQ · 05/14 14:22
Analysts’ Top Healthcare Picks: aTyr Pharma (LIFE), Dynavax (DVAX)
TipRanks · 05/14 14:20
More
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Webull offers Dynavax Technologies Corp stock information, including NASDAQ: DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.